Sugi Predict

Sugi Predict / Compounds / SCHEMBL16058395

SCHEMBL16058395

SCHEMBL16058395

CC(C)(C)OC(=O)NCC1COCCN1C(=O)O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HCRTR2 O43614 1/20 0.40
▸ DRD2 P14416 1/20 0.38
▸ USP2 O75604 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ CTSD P07339 1/20 0.37
▸ CTSL P07711 1/20 0.37
▸ CTSB P07858 1/20 0.37
▸ CTSS P25774 1/20 0.37
▸ BTK Q06187 1/20 0.35
▸ MEN1 O00255 2/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ CKS1B P61024 1/20 0.35
▸ SKP1 P63208 1/20 0.35
▸ SKP2 Q13309 1/20 0.35
▸ GAA P10253 2/20 0.35
▸ PDK1 Q15118 2/20 0.35
▸ PDK2 Q15119 1/20 0.35
▸ PDK3 Q15120 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25267951 1.00 HCRTR2 (0.40) HCRTR2DRD2USP2SMN1; SMN2CTSD
SCHEMBL30567879 0.86 TSHR (0.43) HCRTR2DRD2USP2SMN1; SMN2CTSD
SCHEMBL3942123 0.83 PDK1 (0.39) MEN1KMT2AALDH1A1TSHRGAA
SCHEMBL25267556 0.82 USP2 (0.35) USP2SMN1; SMN2CTSDCTSLCTSB
SCHEMBL25267557 0.82 USP2 (0.35) USP2SMN1; SMN2CTSDCTSLCTSB
SCHEMBL25290598 0.82 DRD2 (0.44) DRD2SMN1; SMN2BTKMEN1KMT2A
SCHEMBL25258556 0.82 DRD2 (0.44) DRD2SMN1; SMN2BTKMEN1KMT2A
SCHEMBL30452743 0.80 MEN1 (0.46) DRD2CTSLMEN1KMT2APDK1
SCHEMBL28185087 0.80 PDK1 (0.36) PDK1PDK2PDK3
SCHEMBL1949579 0.80 BTK (0.43) HCRTR2USP2SMN1; SMN2CTSDCTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118355020-A Therapeutic compounds for HIV virus infection 吉利德科学公司 2024-07-16 — — CN disclosed
US-20230416263-A1 CARM1 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2023-12-28 — — US disclosed
US-11834455-B2 Carm1 inhibitors and uses thereof Epizyme, Inc. (US) 2023-12-05 — — US disclosed
US-20230279020-A9 CARM1 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2023-09-07 — — US disclosed
US-20230203071-A1 THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION GILEAD SCIENCES, INC. 2023-06-29 — — US disclosed
WO-2023102529-A1 THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION GILEAD SCIENCES, INC. (US) 2023-06-08 — — WO disclosed
US-20210155631-A1 CARM1 INHIBITORS AND USES THEREOF EPIZYME INC (US) 2021-05-27 — — US disclosed
US-10633389-B2 CARM1 inhibitors and uses thereof Epizyme, Inc. (US) 2020-04-28 — — US disclosed
US-20190135819-A1 CARM1 INHIBITORS AND USES THEREOF Epizyme, Inc. 2019-05-09 — — US disclosed
US-10118931-B2 CARM1 inhibitors and uses thereof Epizyme, Inc. (US) 2018-11-06 — — US disclosed
US-20180282343-A1 CARM1 INHIBITORS AND USES THEREOF Epizyme, Inc. 2018-10-04 — — US disclosed
US-9856267-B2 CARM1 inhibitors and uses thereof Epizyme, Inc. (US) 2018-01-02 — — US disclosed
US-20170320883-A1 CARM1 INHIBITORS AND USES THEREOF Epizyme, Inc. 2017-11-09 — — US disclosed
US-9738651-B2 CARM1 inhibitors and uses thereof Epizyme, Inc. (US) 2017-08-22 — — US disclosed
WO-2016044641-A2 CARM1 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2016-03-24 — — WO disclosed
US-20160039834-A1 CARM1 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2016-02-11 — — US disclosed
EP-2970219-A1 CARM1 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2016-01-20 — — EP disclosed
WO-2014144169-A1 CARM1 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2014-09-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210155631-A1 CARM1 INHIBITORS AND USES THEREOF CARM1, TIAM1, ADRM1 HCRTR2 3427/4885DRD2 3191/4885USP2 2761/4885
US-10118931-B2 CARM1 inhibitors and uses thereof CARM1, TIAM1, ADRM1 HCRTR2 3427/4885DRD2 3191/4885USP2 2761/4885
US-20230279020-A9 CARM1 INHIBITORS AND USES THEREOF CARM1, TIAM1, ADRM1 HCRTR2 3427/4885DRD2 3191/4885USP2 2761/4885
US-20170320883-A1 CARM1 INHIBITORS AND USES THEREOF CARM1, TIAM1, ADRM1 HCRTR2 3467/4885DRD2 3195/4885USP2 2753/4885
US-11834455-B2 Carm1 inhibitors and uses thereof CARM1, TIAM1, ADRM1 HCRTR2 3467/4885DRD2 3195/4885USP2 2753/4885
US-10633389-B2 CARM1 inhibitors and uses thereof CARM1, TIAM1, ADRM1 HCRTR2 3427/4885DRD2 3191/4885USP2 2761/4885
US-20190135819-A1 CARM1 INHIBITORS AND USES THEREOF CARM1, TIAM1, ADRM1 HCRTR2 3427/4885DRD2 3191/4885USP2 2761/4885
US-20230203071-A1 THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION HAVCR2, MAVS, CD4 HCRTR2 4493/4885DRD2 3554/4885USP2 3517/4885
US-20230416263-A1 CARM1 INHIBITORS AND USES THEREOF CARM1, TIAM1, ADRM1 HCRTR2 3427/4885DRD2 3191/4885USP2 2761/4885
US-20180282343-A1 CARM1 INHIBITORS AND USES THEREOF CARM1, TIAM1, ADRM1 HCRTR2 3467/4885DRD2 3195/4885USP2 2753/4885
US-20160039834-A1 CARM1 INHIBITORS AND USES THEREOF CARM1, TIAM1, ADRM1 HCRTR2 3639/4885DRD2 3173/4885USP2 2736/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback